Last $68.12 USD
Change Today +0.80 / 1.19%
Volume 2.2M
As of 5:15 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
$67.73
Previous Close
$67.32
Day High
$68.55
Day Low
$67.60
52 Week High
11/11/14 - $68.67
52 Week Low
12/17/13 - $48.88
Market Cap
75.8B
Average Volume 10 Days
3.4M
EPS TTM
$2.41
Shares Outstanding
1.1B
EX-Date
11/12/14
P/E TM
28.3x
Dividend
$1.96
Dividend Yield
2.88%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men at high risk of fracture; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency, as well as provides anti-infectives. Its neuroscience products treat major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; attention-deficit hyperactivity disorder; depressive disorder, obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and brain imaging of beta-amyloid neuritic plaques. The company’s oncology products treat pancreatic, metastatic breast, non-small cell lung, ovarian, bladder, colorectal, and head and neck cancers, as well as malignant pleural mesothelioma; and cardiovascular products are used to treat erectile dysfunction and benign prostatic hyperplasia, and pulmonary arterial hypertension, as well as to reduce thrombotic cardiovascular events and as adjunct to percutaneous coronary intervention. In addition, it provides animal health products, such as cattle feed additives; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; leanness and performance enhancers for swine and cattle; protein supplements to enhance milk productivity in dairy cows; anticoccidial agents; and products that prevent flea infestations on dogs, kills fleas, prevent heartworm disease, and control intestinal parasite infections. The company distributes its products through independent wholesale distributors and directly to pharmacies. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

37,925 Employees
Last Reported Date: 02/19/14
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $680.7K
Senior Vice President and General Counsel
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2013.

eli lilly & co (LLY) Key Developments

Boehringer Ingelheim Pharmaceuticals and Eli Lilly Announce Favorable Data from Type 2 Diabetes Analysis

Boehringer Ingelheim Pharmaceuticals, Inc., or BIPI, and Eli Lilly and Company have announced favorable data from a new retrospective analysis, which showed that Empagliflozin tablets reduced hemoglobin A1C, body weight and several markers of abdominal fat in adults with type 2 diabetes, or T2D. The FDA approved empagliflozin, marketed as Jardiance, in August 2014 as an adjunct to diet and exercise to improve glycemic control in adults with T2D. JARDIANCE is not recommended for people with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). JARDIANCE is not approved to reduce body weight or body fat. Patients should not take JARDIANCE if they have severe kidney problems or are on dialysis, or if they are allergic to empagliflozin or any ingredient in JARDIANCE. The study presented at AHA included analyses of two sets of adults with T2D treated with either empagliflozin or placebo. The first group consisted of 823 adults with high blood pressure who were treated for 12 weeks, while the second examined a pool of 2,476 adults from four different trials who were treated for 24 weeks. These randomized studies compared empagliflozin with placebo as an add-on to existing therapy, including metformin, metformin plus sulfonylurea, or pioglitazone with or without metformin. In both groups, treatment with empagliflozin significantly reduced A1C, body weight and several markers of abdominal fat compared with placebo. Changes in estimated total body fat did not reach statistical significance. In the 12-week study of 823 adults with T2D, compared with placebo, for those treated with empagliflozin: A1C was significantly reduced from a baseline of 7.90% by 0.64% with empagliflozin; Body weight was significantly reduced, from a baseline of 95 kg, by 1.7 kg with empagliflozin; and Total body fat percentage, estimated through an equation based on weight and waist circumference, was not significantly reduced, from a baseline of 35%, by 0.2%.

Eli Lilly and Company Announces Availability of Trulicity in U.S. Pharmacies

The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's Trulicity is a once-weekly glucagon-like peptide-1 receptor agonist designed with patients in mind. It comes in a single-dose pen and does not require the patient to mix, measure, or handle the needle. Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Trulicity is not recommended as first-line therapy for patients inadequately controlled on diet and exercise. It has not been studied in patients with a history of pancreatitis, and other antidiabetic therapies should be considered for patients with a history of pancreatitis. Trulicity is not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Trulicity is not a substitute for insulin and has not been studied in combination with basal insulin. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is not for patients with pre-existing severe gastrointestinal disease. Trulicity has a Boxed Warning about potential risk of thyroid c-cell tumors including medullary thyroid carcinoma. It is contraindicated in patients with a personal history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 and in patients with a prior serious hypersensitivity reaction to dulaglutide or any of its product components. The U.S. Food and Drug Administration approved Trulicity on September 18, 2014 based on results from a number of studies of Trulicity used alone or in combination with commonly prescribed diabetes medications, including metformin, pioglitazone, glimepiride, and insulin lispro. It is now available to patients in 0.75 mg and 1.5 mg doses, delivered in the single-dose Trulicity pen. In a separate usability study, most patients agreed the Trulicity pen was easy to use. To help make the cost of therapy more manageable, the Trulicity Savings Card can reduce out-of-pocket costs to $25 for each prescription of Trulicity for a maximum of two years. This is available for commercially insured patients only. Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Trulicity is not recommended as first-line therapy for patients inadequately controlled on diet and exercise. It has not been studied in patients with a history of pancreatitis, and other antidiabetic therapies should be considered for patients with a history of pancreatitis. Trulicity is not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Trulicity is not a substitute for insulin and has not been studied in combination with basal insulin. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is not for patients with pre-existing severe gastrointestinal disease. Important Safety Information for Trulicity. In male and female rats, dulaglutide causes dose-related and treatment duration dependent increase in the incidence of thyroid C-cell tumors after lifetime exposure. It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans as human relevance could not be determined from clinical or nonclinical studies. Trulicity is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value in patients treated with Trulicity. Counsel regarding the risk factors and symptoms of thyroid tumors. Trulicity is contraindicated in patients with a prior serious hypersensitivity reaction to dulaglutide or any of the product components. Risk of Thyroid C-cell Tumors: Counsel patients regarding the risk of medullary thyroid carcinoma and the symptoms of thyroid tumors. Patients with elevated serum calcitonin and patients with thyroid nodules noted on physical examination or neck imaging should be referred to an endocrinologist for further evaluation. Pancreatitis: Has been reported in clinical trials. Observe patients for signs and symptoms including persistent severe abdominal pain. If pancreatitis is suspected discontinue Trulicity promptly. Do not restart if pancreatitis is confirmed. Consider other antidiabetic therapy. Hypoglycemia: The risk of hypoglycemia is increased when Trulicity is used in combination with insulin secretagogues or insulin. Patients may require a lower dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia. Hypersensitivity Reactions: Systemic reactions were observed in clinical trials in patients receiving Trulicity. Instruct patients who experience symptoms to discontinue Trulicity and promptly seek medical advice. Renal Impairment: In patients treated with GLP-1 RAs there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, sometimes requiring hemodialysis. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea or dehydration. In patients with renal impairment, use caution when initiating or escalating doses of Trulicity and monitor renal function in patients experiencing severe adverse gastrointestinal reactions. Severe Gastrointestinal Disease: Use of Trulicity may be associated with gastrointestinal adverse reactions sometimes severe. Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients. Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Trulicity or any other antidiabetic drug. The most common adverse reactions reported in >=5% of Trulicity-treated in placebo-controlled trials were nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia and fatigue. Gastric emptying is slowed by Trulicity, which may impact absorption of concomitantly administered oral medications. Use caution when oral medications are used with Trulicity. Drug levels of oral medications with a narrow therapeutic index should be adequately monitored when concomitantly administered with Trulicity. Pregnancy: There are no adequate and well-controlled studies of Trulicity in pregnant women. Use only if potential benefit outweighs potential risk to fetus. Nursing Mothers: It is not known whether Trulicity is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue Trulicity taking into account the importance of the drug to the mother. Pediatric Use: Safety and effectiveness of Trulicity have not been established and use is not recommended in patients less than 18 years of age.

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves CYRAMZA

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA(R) (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. CYRAMZA now has two FDA approvals for these patients. This FDA approval of CYRAMZA represents another milestone for people battling this devastating and difficult-to-treat disease. This FDA approval for CYRAMZA is based on the Phase III RAINBOW trial, which compared CYRAMZA plus paclitaxel to placebo plus paclitaxel. Efficacy endpoints in the trial included the major efficacy outcome measure of overall survival and the supportive efficacy outcome measures of progression-free survival and objective response rate. The labeling for CYRAMZA contains a Boxed Warning regarding increased risk of hemorrhage, including severe and sometimes fatal hemorrhagic events. CYRAMZA should be permanently discontinued in patients who experience severe bleeding.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:US $68.12 USD +0.80

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.51 USD +0.26
AbbVie Inc $69.20 USD +0.50
Actavis plc $270.61 USD +0.14
AstraZeneca PLC 4,780 GBp +59.50
Teva Pharmaceutical Industries Ltd $56.98 USD +0.17
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 26.9x
Price/Sales 3.5x
Price/Book 4.1x
Price/Cash Flow 27.9x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.